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Abstract
There is increasing evidence that subjective cognitive decline (SCD) in individuals with 
unimpaired performance on cognitive tests may represent the first symptomatic manifestation of 
Alzheimer’s disease (AD). The research on SCD in early AD, however, is limited by the absence 
of common standards. The working group of the Subjective Cognitive Decline Initiative (SCD-I) 
addressed this deficiency by reaching consensus on terminology and on a conceptual framework 
for research on SCD in AD. In this publication, research criteria for SCD in pre-mild cognitive 
impairment (MCI) are presented. In addition, a list of core features proposed for reporting in SCD 
studies is provided, which will enable comparability of research across different settings. Finally, 
a set of features is presented, which in accordance with current knowledge, increases the 
likelihood of the presence of preclinical AD in individuals with SCD. This list is referred to as 
SCD plus.
Keywords
Alzheimer’s disease; Subjective cognitive decline; Preclinical Alzheimer’s disease; Mild cognitive 
impairment; Prodromal Alzheimer ’s disease; Research criteria
1. Introduction
Characterization of at-risk states and detection of early disease are crucial for targeted 
dementia prevention [1]. The development of Alzheimer’s disease (AD), the most common 
cause of dementia, is slow and progressive with a presymptomatic course over several years 
to decades [2,3]. Biomarkers are available for some of the core features of AD pathology. 
These biomarkers include cerebrospinal fluid Aβ42, total tau, and phosphorylated tau (ptau) 
concentrations, positron emission tomography of brain amyloid deposition and glucose 
metabolism, and brain atrophy on magnetic resonance imaging [4].
Recently, two similar concepts have been proposed that subdivide the course of AD into 
three subsequent stages. The International Working Group (IWG) proposed (1) the 
asymptomatic at-risk stage of AD (AD pathology evidenced by biomarkers and no 
symptoms), (2) prodromal AD (episodic memory deficit with impaired cued recall that can 
be isolated or in association with other cognitive changes and biomarker evidence for AD), 
and (3) AD dementia (dementia and biomarker evidence for AD) [5,6]. The US National 
Institute on Aging-Alzheimer’s Association (NIA-AA) group proposed (1) the preclinical 
stage of AD (no impairment in cognition on standard assessments and biomarker evidence 
for AD), (2) mild cognitive impairment (MCI) due to AD (impairment on memory or other 
domains of cognition on a standard assessment and biomarker evidence for AD), and (3) 
dementia due to AD (dementia and biomarker evidence for AD) [7–10]. Those stages before 
dementia may serve to define the population for targeted dementia prevention trials. 
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Currently, studies with potentially disease-modifying drugs are being performed in 
prodromal AD and MCI due to AD (www.clinicaltrials.gov). At these stages, however, 
progressive neuronal loss and irreversible cognitive impairment may have already occurred. 
Thus, conceptualization and investigation of the preprodromal or pre-MCI stage of AD is 
needed to define target populations for interventions at a stage of only mild neuronal 
damage and with still sufficient functional compensation [11].
In accordance with the NIA-AA criteria, stage 3 of pre-clinical AD is defined by biomarker 
evidence for AD plus subtle cognitive decline, which does not reach the level of objective 
impairment required for the MCI diagnosis. This subtle cognitive decline is difficult to 
detect on standardized cognitive testing because of the requirement of high test sensitivity, 
robustness of tests against within-subject performance variability, specificity of test results 
in the differentiation from normal performance, and test stability against rater-related 
confounds in application. The subtle decline is also associated with at least partly successful 
compensation, yielding unimpaired performance levels on some individual tests.
Limitations in detecting this subtle decline on cognitive tests, however, do not preclude self-
experience of this decline in individuals with preclinical AD. In fact, subjectively reported 
change in cognitive performance is a core criterion of the MCI and prodromal AD definition 
[5,9,12]. There is rapidly increasing evidence that this subjectively experienced decline even 
at the stage of normal performance on cognitive tests (pre-MCI and preprodromal) is 
associated with increased likelihood of biomarker abnormalities consistent with AD 
pathology and with an increased risk for future cognitive decline and AD dementia (e.g., 
[13–35]). Valid usage of subjective reports on cognitive decline as an indicator of first 
effects of AD pathology on cognition would therefore be of significant benefit. As the report 
of subjective decline reflects a longitudinal course, it may even prove to be particularly 
informative at a very early disease stage, in which detection of decline with cross-sectional 
cognitive tests is challenging (preclinical AD). At this stage, it may reflect the first effects of 
AD pathology on cognitive functioning between full compensation and very first decline 
(Fig. 1). Future effective treatment at this stage would preserve function at a high level.
However, subjective decline in cognition is unspecific. It is related to numerous conditions 
such as normal aging, personality traits, psychiatric conditions, neurologic and medical 
disorders, substance use, and medication. It may also be affected by the individual cultural 
background. Refinement of knowledge about the characteristics of subjective decline at the 
very early (preclinical) stage of AD is therefore needed.
Results of current studies on subjective cognitive decline (SCD) in preclinical AD are highly 
variable and a conclusive picture with regard to rate of decline, risk for conversion to AD 
dementia, role of biomarkers in disease course prediction, and other crucial questions is 
missing [36–38]. This is partly due to a dearth of common terminology and viable research 
concepts on this topic. For example, after the initial description in 1982 [39], the reported 
experiences of cognitive decline have been denoted and conceptualized as subjective 
cognitive impairment, subjective memory decline, subjective memory impairment, and 
memory complaints, among other terminologies [40]. Different strategies are applied for 
assessment ranging from a single question or a small number of items with varied content 
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and unknown measurement properties to more comprehensive, psychometrically derived, 
and validated questionnaires. Moreover, participants are studied in different research 
environments, including clinical settings, volunteer samples, and population-based cohorts.
A common concept for terminology and research procedures is critically needed to achieve a 
collective and improved understanding of the subjective experience of cognitive decline, to 
elaborate its role in identifying individuals with preclinical AD, and to assess its potential 
usefulness for clinical trials recruitment. To address this need, the Subjective Cognitive 
Decline Initiative (SCD-I) was started with the aim of facilitating the development of a 
common SCD research concept.
2. Procedures
The SCD-I was launched in October 2012 and a working group was formed, including 
researchers from clinical and population-based science on AD who have investigated the 
topic of SCD. Researchers were identified by systematic literature search. In addition, the 
initiative sought to include the leaders of the IWG and NIA-AA preclinical AD working 
groups and key representatives of the large ongoing studies on early AD detection 
(Alzheimer’s Disease Neuroimaging Initiative (ADNI); Australian Imaging, Biomarker & 
Lifestyle Flagship Study of Ageing (AIBL); Dementia Competence Network (DCN); 
Development of screening guidelines and criteria for predementia Alzheimer’s disease 
(DESCRIPA); Sydney Memory and Ageing Study, Determinants and Evolution of 
Alzheimer’s Disease and Related Disorders (MEMENTO); DZNE Longitudinal Study og 
Cognition and Dementia (DELCODE); and Mayo Clinic Study of Aging). All contacted 
investigators agreed to participate. After confirmation of participation, a set of key points 
and definitions was distributed. This was followed by three rounds of comments and 
discussion with subsequent modifications of the key points and definitions. After consenting 
to the content, the present manuscript was drafted and approved by all participants of the 
SCD-I working group.
3. Key points on SCD in preclinical AD
The SCD-I working group agreed on the following key points:
1. There is evidence that SCD occurs at the preclinical stage of AD and may serve as 
a symptomatic indicator of preclinical AD because (a) longitudinal data support 
SCD as a risk factor for future cognitive decline as well as for MCI and AD 
dementia (e.g., [13,14,33–35]), (b) there is cross-sectional biomarker evidence for 
an increased prevalence of preclinical AD in those with SCD (e.g. [15–31]), and (c) 
individuals with SCD and biomarker evidence for AD are at increased risk of future 
cognitive decline and progression to MCI and AD dementia [41–43].
2. Current knowledge is insufficient to comprehensively define the specific features 
of SCD in preclinical AD. The characteristics of SCD in preclinical AD are 
probably variable and are expressed heterogeneously.
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3. Preclinical AD is, by definition, a biomarker diagnosis, and SCD is neither required 
for the diagnosis of preclinical AD nor is it necessarily present in all cases of 
preclinical AD. SCD by itself may never be sufficient to diagnose preclinical AD.
4. Numerous causes of SCD other than preclinical AD exist. These include, but are 
not limited to, SCD in MCI due to AD/prodromal AD, dementia, normal aging, 
psychiatric and neurologic disorders other than AD, or related to effects of 
medication and substance use.
4. Aims of the SCD framework
The first aim of this framework was to create a common concept and terminology to 
facilitate research on various aspects of SCD in different research settings and at the same 
time generate comparability and synergies across studies. This is achieved by defining terms 
and proposing a broad symptomatic definition of pre-MCI SCD (Table 1).
It is acknowledged that any definition of SCD is a trade-off between being overinclusive 
(high sensitivity and high false positive rates) and being too restrictive (high specificity and 
high false negative and high screening failure rates). At the present state, a sensitive and 
potentially overinclusive definition was considered appropriate as the specific features of 
SCD in preclinical AD are not yet well known.
In addition, we propose a system for coding essential features of SCD, which investigators 
may adopt as a common core of future studies of SCD. This coding system will support the 
standardization of assessments of SCD across studies. Eventually, this will enable the 
identification of SCD subtypes, which may serve different research purposes (Table 2).
A further aim of the framework is to list specific features associated with SCD, which 
increase the likelihood of the presence of preclinical AD. This list of features may be useful 
for studies that wish to use SCD as a symptomatic marker for enrichment of preclinical AD 
but do not specifically aim at elaborating SCD itself. This list of features is referred to as 
SCD plus (preclinical AD) (Table 3). It is an open set of criteria reflecting current 
knowledge, which allows for addition and subtraction of items as research progresses.
5. Terminology of SCD
The rationale and meaning of the term of subjective cognitive decline are the following: 
Subjective refers to the self-perception of cognitive performance. It is conceptually 
independent of performance on a cognitive test. No “validation” of the subjective experience 
of cognitive capability by means of cognitive testing is required. The performance on a 
cognitive test is the objective level of cognitive functioning at a particular point in time. The 
concurrent and longitudinal relationship between subjective and objective cognitive 
performance is a research topic of major interest (e.g., [44]).
In the context of SCD in preclinical AD, cognitive testing is required to establish a normal 
objective performance level, which defines preclinical AD. If SCD is studied in other 
conditions than preclinical AD, the respective criteria set for these conditions (e.g. MCI) 
need to be applied.
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Cognitive refers to any cognitive domain. It is not restricted to memory. Cognitive as 
opposed to memory was chosen for the following reasons: (1) the first symptoms of AD are 
not limited to memory decline and (2) lay people may report memory decline when they 
actually experience decline in other cognitive domains such as executive function and vice 
versa (e.g., reporting a “speech problem” when the difficulty is really memory retrieval). 
Currently, many studies have used questions specifically related to episodic memory, and 
the available evidence for an association of preclinical AD with questions about memory 
functioning may be strongest at present. Therefore, a positive response to the question on 
subjective memory is proposed as an item of the SCD plus category. Broader application of 
instruments that extend beyond the assessment of subjective memory decline [29,39,45,46], 
the development and elaboration of questions on subjective change in other cognitive 
domains (e.g., executive function, attention, language, and visuospatial function), and the 
association of these with preclinical AD or other diseases are core topics for current and 
future SCD research.
Decline refers to a subjectively experienced worsening of cognitive capacities. It was chosen 
because it reflects the progressive nature of cognitive deterioration in AD. It is 
acknowledged that this term also incorporates conditions such as normal aging. There is 
evidence that additional characteristics of this decline increase the likelihood of an 
association with preclinical AD. These include (1) the association of decline with a 
particular concern (worries) [34] and (2) the appraisal that one’s own cognitive capacity is 
inferior compared with others of the same age group [19,20]. These two features are 
proposed for the SCD plus category.
Studies on SCD have often used the term impairment (subjective cognitive impairment) 
instead of decline. The term impairment does not immediately reflect the temporal course of 
subjective cognitive change because impairment may also be of a chronic and stable nature. 
Thus, it requires an additional definition of onset. In contrast, the term decline already 
includes the fact that an onset has occurred. However, the condition of subjective 
impairment in cognition may indicate a certain level of severity of SCD, which is 
characterized by a subjectively experienced impairment (i.e., feeling handicapped or 
functionally defective) as opposed to just a worse level of cognitive functioning from some 
prior time [39,47,48]. Therefore, it is proposed that SCD studies code whether an individual 
experiences impairment because of decline in cognitive capacity. This coding system 
permits the assessment of the specific prediction of AD based on subjective cognitive 
impairment within the SCD framework.
6. Onset of SCD
One feature of decline is the time frame of onset. There is evidence that the onset of SCD 
within a few years may be more predictive of cognitive decline and AD than the presence of 
SCD for several years [14,49,50]. It is also acknowledged that an individual’s recall of the 
time of onset of SCD may be vague. It is suggested to code the reported SCD onset in 
studies on SCD but not to define an onset limit in the core criteria of SCD. An onset within 
the last 5 years [14,49,50] is suggested as a component of SCD plus.
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7. Age at the onset of SCD
Age at the onset of SCD should also be coded in SCD studies. This is defined as the age at 
which the individual first experienced a significant and persistent decline that does not just 
occur as transient or short term. No age at onset cutoff is defined as an SCD core criterion 
because different research settings may require different age ranges. As an example, highly 
specialized memory clinic settings may sample individuals with AD at a younger age than 
broad population-based studies. For the SCD plus category, in studies of preclinical AD that 
are unrelated to autosomal dominant genetic mutations, a reported age of onset at 60 years 
or older is proposed. The rationale for this cutoff is the increasing prevalence of AD-related 
neuropathological alterations starting at midlife, which may trigger SCD after neuronal 
dysfunction affects cognitive abilities. At younger age cutoffs, the likelihood of SCD due to 
causes other than AD increases. It is acknowledged that this age cutoff is arbitrary and may 
not be appropriate for all studies. We caution that subjects with early-onset AD may 
experience SCD earlier and may be missed by this proposed criterion. Thus, studies may 
apply other age cutoffs, depending on the population of interest, but should code the age at 
onset to allow comparison with other investigations.
8. Confirmation of cognitive decline by others
SCD conceptually refers to the self-perception of cognitive decline and does not require 
confirmation by external observation per se. For this reason, confirmation by an informant is 
not a core criterion of SCD.
However, cognitive decline may be observed by others in contact with the individual. In 
fact, there is evidence suggesting that informant report may be a better predictor of objective 
performance than self-report and may facilitate identification of very early decline related to 
AD (e.g., [44,47,48,51,52]). This may be particularly the case in advanced stages of 
preclinical AD in proximity to MCI [53]. In contrast, recent data suggest that earliest 
changes in cognition are best perceived by the individual rather than by an observer [54]. 
This finding may be related to still successful functional compensation at the stage of early 
SCD.
Finally, there are individuals at the early AD stage with observed cognitive decline but 
without self-reported SCD (e.g., [55]). These do not fall into the SCD category. They may 
represent a group with very early anosognosia or denial in the course of the disease and may 
be of particular research interest.
It is proposed to code whether SCD is confirmed by an informant in studies on SCD. It has 
to be acknowledged, however, that the observation and report by others may be affected by 
several issues such as frequency of contact, quality of the relationship, expectations, 
affective state of the individual or informant, etc. Thus, refinement and standardization of 
the assessment of informant report on SCD is an important research topic.
It is suggested to include confirmation by an informant as an SCD plus feature because it 
may serve as an enrichment strategy for preclinical AD, particularly at the progressed stage 
of SCD (e.g., [16,44,48,51,52]).
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9. Psychiatric comorbidities, subthreshold symptoms, and personality 
traits
It is acknowledged that various psychiatric disorders can be associated with SCD. If SCD 
criteria are applied in the context of research on preclinical AD, the presence of major 
psychiatric disorders should be an exclusion criterion because AD-related SCD should not 
be confounded by other conditions that clearly affect the subjective experience of cognitive 
capacity. The delineation of the very first symptomatic manifestation of AD in subjects with 
major depression or generalized anxiety disorder is, however, a particular research topic, 
which may yield specific characteristics of AD-related SCD in these conditions. 
Furthermore, SCD in psychiatric disorders, independent of preclinical AD, is considered an 
important topic and relevant subject of future conceptualization and research.
In many studies on SCD in preclinical AD, individuals report subthreshold symptoms of 
depression and anxiety. Slightly higher scores on scales that measure these conditions 
frequently document this finding. These subjects, however, do not necessarily fulfill the 
criteria for a psychiatric disorder. It is proposed that subthreshold symptoms of depression 
and anxiety are assessed with respective scales and to account for them in statistical models 
but not to exclude subjects with subthreshold symptoms from studies on SCD in preclinical 
AD. These subthreshold symptoms may also be manifestations of preclinical AD.
There is literature suggesting that SCD is associated with certain personality traits such as 
neuroticism and anxiety sensitivity and related inversely with measures of openness and 
conscientiousness [44,56,57]. Personality traits can be captured with respective instruments 
in studies on SCD, but there is no specific pattern of personality characteristics that at 
present should be defined as an exclusion criterion.
10. Neurologic and medical comorbidities as well as medications
Several neurologic and medical conditions as well as medications can affect cognition and 
may be associated with SCD. An explicit list of conditions and drugs will always be 
incomplete. Therefore, investigators in SCD studies should document comorbidities and 
medications and report whether these were treated as exclusion criteria or considered 
otherwise in the respective studies.
11. Apolipoprotein E genotype
There is evidence from some memory clinic and population-based studies of an 
overrepresentation of the APOE ε4 allele in SCD, a particular association of APOE ε4 and 
biomarker evidence for AD in SCD, and an effect of APOE ε4 on the prospective risk of 
cognitive decline in SCD [58–61]. To further elucidate the potential use of the APOE 
genotype in predicting preclinical AD and cognitive decline in SCD, it should be reported in 
SCD studies, if available. As APOE ε4 is a valid genetic risk factor for AD, it is proposed as 
an SCD plus feature.
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12. Research setting
The setting in which SCD subjects are recruited is considered a crucial factor in determining 
the characteristics of the respective samples. All SCD studies should explicitly describe their 
recruitment strategy and describe the setting. Typical research settings include (1) 
population-based studies, (2) volunteer samples, and (3) medical help–seeking samples. The 
latter include, but are not limited to, patients consulting general practitioners, neurologists, 
psychiatrists, and geriatricians or attending memory clinics. In research in the medical 
environment, the terms complaint or complainers are frequently used. In many countries, 
these terms and their equivalents in other languages have negative connotations. It is 
therefore suggested to preferentially use the term medical help seeking, which can be 
associated with particular concerns.
13. Perspectives
The proposed framework on SCD in preclinical AD aims at standardizing research on self-
perceptions of change and symptom development at very early disease stages before the 
detection threshold of current neuropsychological instruments is reached. This particular 
nature of SCD represents a challenge regarding research designs and modes of assessment. 
However, it can potentially provide highly valuable information for early disease detection 
and disease course prediction. The common framework will serve as the basis for joint 
research efforts, synergies across studies, and elaboration of knowledge about SCD.
The application of a refined SCD approach as an enrichment strategy for preclinical AD 
studies is distinct from other current approaches, which select on the basis of biological 
criteria (causal mutation carriers, APOE ε4 carriers, and amyloid-positive cognitively 
normal individuals). Although highly plausible, there may be selection bias associated with 
these approaches because they depend on an a priori biological hypothesis, and findings 
from these enrichment approaches may not be generalizable to all AD cases. In comparison, 
SCD is a much more liberal and broad enrichment strategy that potentially captures 
additional AD cases. This may, however, be at the expense of specificity. A particular 
advantage of enrichment by SCD is its practicality and low cost of application. It is 
applicable in different settings and most likely preselects subjects who are willing to 
participate in trials and who will receive future treatments.
This proposal focuses on SCD in preclinical AD. As with previous research criteria on 
prodromal AD and MCI due to AD, the SCD and SCD plus criteria require continuous 
refinement and validation to eventually serve as a standardized indicator for biomarker-
based preclinical AD detection. This research framework is a central step in this process.
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Glossary
Subjective 
cognitive 
decline (SCD)
Self-perceived decline in any cognitive domain over time. The 
category SCD does not require cognitive testing or confirmation of 
cognitive decline by an informant. SCD is not associated with a 
particular disease or disease state per se. When reporting on SCD, the 
specific disease condition to which it refers in the particular context 
needs to be added (e.g., SCD in pre-clinical AD). If these conditions 
have specific definitions, these need to be established. As an example, 
in the case of SCD in preclinical AD, cognitive testing is needed to 
exclude cognitive impairment (e.g., MCI)
Objective 
cognitive 
performance 
level
Performance on a cognitive test
Preclinical 
Alzheimer’s 
disease (AD)
Preclinical AD describes the stage at which AD pathology is present, 
but the objective cognitive performance still reaches a level within the 
normal age-, gender-, and education-adjusted range on standardized 
cognitive tests. It includes the presence of subtle cognitive decline, 
which has not yet reached the level of a clinical symptom [8]. SCD 
can be a reflection of subtle cognitive decline in preclinical AD. SCD, 
however, is not a requirement in the preclinical AD definition [8]
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RESEARCH IN CONTEXT
1. Systematic review: We reviewed the literature on subjective cognitive decline 
(SCD) in relation to Alzheimer’s Disease. We included population-based studies 
and studies in clinical samples.
2. Interpretation: We consented a framework for research on SCD in the context of 
preclinical AD. This framework includes a broad definition of pre-mild 
cognitive impairment SCD, features to be reported in SCD studies and a set of 
criteria, which increase the likelihood of the presence of preclinical AD in 
individuals with SCD (SCDplus). The consented research framework is the 
basis for increased comparability of research on SCD across settings and studies
3. Future directions: Refined understanding of several aspects of SCD is required 
to employ it as an indicator of the earliest symptomatic manifestation of AD. 
Further conceptual work and harminisation processes will guide this process.
Jessen et al. Page 14
Alzheimers Dement. Author manuscript; available in PMC 2015 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 1. 
Depicted is the course of cognitive decline in relation to progressive disease pathology in 
Alzheimer’s disease (AD). After a phase of stable cognitive performance in the presence of 
increasing pathology, cognitive decline occurs. After crossing the threshold of below normal 
age-, sex-, and education-adjusted performance, the stage of mild cognitive impairment 
(MCI) or prodromal AD is reached. Subsequently, cognitive decline progresses onward to 
the stage of dementia. It is proposed that SCD occurs at the late stage of preclinical AD, 
which is characterized by increasing compensatory cognitive efforts and subtle cognitive 
decline. Thus, SCD may indicate the late-stage preclinical AD before the threshold of MCI/
prodromal AD is reached. There is evidence that the subjective experience of decline levels 
off as disease progresses into dementia. That stage, however, is not part of the 
conceptualization of SCD in preclinical AD and is not addressed in the present publication.
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Table 1
Research criteria for pre-MCI subjective cognitive decline (SCD)
1 Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute 
event.
2 Normal age-, gender-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild 
cognitive impairment (MCI) or prodromal AD.
1 and 2 must be present
Exclusion criteria
• Mild cognitive impairment, prodromal AD, or dementia
• Can be explained by a psychiatric* or neurologic disease (apart from AD), medical disorder, medication, or substance use
Abbreviation: AD, Alzheimer’s disease.
*
Individual symptoms of depression or anxiety, which do not reach the threshold of a disorder, are not considered exclusion criteria.
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Table 2
Features suggested for coding in studies on SCD
• Setting in which SCD is expressed
– Medical environment.
♦ Memory clinic, memory specialist
♦ General practitioner
– Population sample
– Volunteer sample (recruitment by advertisement)
– Other, specify
• Association of SCD with medical help seeking (yes/no)
• Report of SCD (spontaneously/on request)
• Onset of SCD (number of years)
• Age at onset of SCD
• Subjective decline in memory (yes/no)
• Subjective decline in nonmemory domains (yes/no), if yes, specify
• Concerns (worries) associated with SCD (yes/no)
• Feeling of worse performance than others of the same age group (yes/no)
• Association of SCD with experience of impairment (yes/no)
• Confirmation of cognitive decline by an informant (yes/no)
• Score on a depression scale, score on an anxiety scale
• APOE genotype, if available
Abbreviation: SCD, subjective cognitive decline.
Alzheimers Dement. Author manuscript; available in PMC 2015 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Jessen et al. Page 18
Table 3
Features that increase the likelihood of preclinical AD in individuals with SCD according to current data: SCD 
plus (preclinical AD)
• Subjective decline in memory, rather than other domains of cognition
• Onset of SCD within the last 5 y
• Age at onset of SCD ≥60 y
• Concerns (worries) associated with SCD
• Feeling of worse performance than others of the same age group
If available or possible to obtain in the respective study:
• Confirmation of cognitive decline by an informant
• Presence of the APOE ε4 genotype
• Biomarker evidence for AD (defines preclinical AD)
Abbreviations: AD, Alzheimer’s disease; SCD, subjective cognitive decline.
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